Navigation Links
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Date:7/29/2008

ble programs. The most advanced compounds in development include VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
2. Indevus Announces Management Changes
3. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
4. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
5. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
6. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
7. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
8. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
9. Indevus Announces Allergan as New Partner for SANCTURA Brand
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... together supply chain risk management and resiliency practitioners with luminaries and thought leaders ... practices, and be recognized for their innovations and performance excellence. At that time ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Argentina Biomedical Sensors Market - Growth, ... The Argentina Biomedical Sensors market is ... of 1.17% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/31/2015)... 2015  For people with Down syndrome, news from ... biotechnology company, located in the Science + Technology Park ... potential therapies yet for people with Down syndrome and other ... Down syndrome and Edwards syndrome aneuploidies in human cell ... . Elixirgen plans to develop this technology into a ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2
... CRY ),a biomaterials, medical device and tissue ... 2008 Cardiac Allograft Symposium at its,corporate headquarters training ... will focus on current clinical outcomes, indications and,surgical ... the CryoValve(R) SG pulmonary human heart valves., ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today ... controlling interest in Jiangsu,Institute of Microbiology Co., Ltd. ... the People,s Republic of China. JSIM,has several drugs ... its development pipeline. This acquisition is expected to ...
... United,Therapeutics Corporation (Nasdaq: UTHR ) announced today ... results before the open of market,on Thursday, May ... half-hour teleconference on Thursday,May 1, 2008, at 9:00 ... 1-800-603-1777, with international callers dialing 1-706-679-8129.,A rebroadcast of ...
Cached Biology Technology:CryoLife Conducts Surgeons Cardiac Allograft Symposium 2Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 27 SAFC®, a member of the Sigma-Aldrich® Group ... investment program to expand its Lenexa, KS , ... seamless upstream and downstream production of dry powder media and ... designed to better serve the biopharmaceutical industry by creating ,Centers ...
... , April 27 Negotiations broke off early Tuesday morning between ... Professionals (PASNAP) following a 14-hour session.  Talks are expected to resume later today at ... Continued progress was reported, ... , , ...
... MDC ) today announced that its board of directors has declared a regular quarterly ... common stock.  The dividend will be paid on Wednesday, May 26, 2010 to ... , , ... , Since 1972, MDC,s subsidiary ...
Cached Biology News:SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 2SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 3SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 4SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 5M.D.C. Holdings Declares Quarterly Cash Dividend 2
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... was developed for culturing hybrid cells that ... consists of doubling the amino acids and ... concentrations have been altered as well. This ... liter, which may render it unsuitable for ...
... is an 18 amino acid synthetic peptide whose sequence corresponds to ... peptide is (amino to carboxy terminus): M(1) - A - S ... A - S - P - R - D - A ... peptide may be used for neutralization and control experiments with the ...
... EpiTect Bisulfite Kit enables complete conversion ... less than 6 hours. The highly ... against DNA degradation and a spin-column-based ... fast and reliable results for all ...
Biology Products: